1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Alligator Bioscience AB

Alligator Bioscience AB

0.01
SEK
+0.00
(-1.85%)
74.25MMarket Cap
Oct 22Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
107.17
21.21
17.47
8.27
1.34
1.52
3.6
6.65
5.33
1.91
0.02
- -
Basic EPS, GAAP
-24.01
76.69
-17.61
-19.58
-46.01
-64.44
-50.01
-39.38
-36.05
-22.79
-7.74
-1.87
- -
Free Cash Flow per Basic Share
-20.88
75.02
-15.09
-34.96
-34.28
-56.21
-49.37
-35.31
-32.33
-17.58
-7.34
-5.77
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
21.43
124.13
207.37
189.51
143.62
79.28
35.34
31.88
10.06
0.74
-7.07
0.11
0.01
Tangible Book Value per Share
4.51
110.55
201.16
183.56
137.76
73.56
29.71
29.83
8.02
-0.38
-8.57
-0.51
-0.06
Basic Weighted Avg Shares
3
3
3
3
3
3
3
4
5
11
30
28
322
Sales/Revenue/Turnover
- -
290
58
57
27
4
4
13
36
58
58
1
- -
Operating Margin (%)
- -
69.36
-59.39
-108.98
-564.52
-4,891.49
-3,309.65
-1,101.85
-538.72
-429.19
-328.37
-23,669.26
- -
Depreciation Expense
3
13
25
3
6
12
12
11
12
10
49
-10
- -
Net Income, GAAP
-77
207
-48
-64
-150
-210
-143
-142
-193
-249
-234
-51
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
71.56
-83.03
-112.1
-556.58
-4,821.29
-3,292.65
-1,095.08
-541.81
-427.81
-404.89
-9,990.27
- -
Working Capital
12
351
652
508
378
165
80
252
58
-21
-130
-9
-17
LT Debt
- -
- -
- -
- -
- -
11
6
4
16
8
33
26
21
Total Equity
69
397
676
618
468
258
115
282
89
12
-131
7
3
Return on Invested Capital (%)
- -
87.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
89.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
89.1
-9.01
-9.85
-27.63
-57.82
-76.68
-71.31
-104.17
-492.71
- -
- -
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
18
9
9
LT Borrowings
- -
- -
- -
LT Finance Leases
26
23
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
628
628
Market Capitalization
15
74
74

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
69
53
24
Cash, Cash Equivalents & STI
62
33
17
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
78
30
41
Payables & Accruals
- -
- -
- -
ST Debt
18
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-137.97%
-263.4%
-105.25%
Free Cash Flow
11.79%
4.84%
-28.35%
Net Income, GAAP
3.2%
-4.01%
-78.05%
Sales/Revenue/Turnover
11.75%
67.25%
-99.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7
8
1
42
58
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.92
-1.07
-1.41
-1.78
-7.74
2025
-0.54
-0.08
- -
-0.66
-1.87
2026
- -
-0.06
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Søren Bregenholt
Full Time Employees
11
Sector
Health technology
Industry
Biotechnology
Address
Medicon Village Lund SN Sweden 223 81
IPO Date
Nov 23, 2016
Website
alligatorbioscience.se
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Alligator Bioscience AB (publ) is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs for cancer treatment. The company specializes in agonist mono- and bispecific antibodies targeting immune pathways such as CD40 and 4-1BB to activate the patient's immune system within the tumor microenvironment; its lead product candidate is mitazalimab, a CD40-targeting agonist antibody in preparation for Phase 3 trials in first-line metastatic pancreatic cancer following positive Phase 2 OPTIMIZE-1 results showing unprecedented 24-month survival outcomes; additional pipeline assets include ATOR-1017, a 4-1BB agonist monoclonal antibody in Phase 1 for solid tumors; ALG.APV-527, a 4-1BB x 5T4 bispecific T-cell engager co-developed with Aptevo Therapeutics in Phase 1 for solid metastatic tumors; ATOR-4066, a preclinical tumor-directed bispecific using the Neo-X-Prime platform; and early-stage candidates from proprietary platforms ALLIGATOR-GOLD (human antibody library), ALLIGATOR-FAB (scaffolded Fab library), FIND (molecular evolution technology), and RUBY (bispecific format). Alligator operates primarily in Sweden and Finland with global partnerships, targeting high-unmet-need solid tumors through early-stage drug development up to Phase 2 clinical trials. Founded in 2001 and headquartered in Lund, Sweden, the company maintains collaborations including a 2021 research and license agreement with Orion Corporation for RUBY-based bispecifics, a 2017 co-development pact with Aptevo for ALG.APV-527, and agreements with BioArctic, MacroGenics, Biotheus, and Abclon (via subsidiary Atlas Therapeutics) for antibody technologies and licensed programs like AC101 in Phase 2 by Shanghai Henlius; recent developments encompass a rights issue announced October 2025 for SEK 120 million to fund 6-9 months of operations into 2026, February 2025 top-line data validating the 900 µg/kg mitazalimab dose for Phase 3, an August 2025 R&D event highlighting the pipeline, peer-reviewed publication of ATOR-1017 clinical data in January 2025, FDA Orphan Drug Designation, and a January 2024 US patent for ATOR-4066.